Showing 4731-4740 of 8223 results for "".
- Hoth Therapeutics Obtains Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/hoth-therapeutics-obtains-full-licensing-rights-for-biolexa-platform-atopic-dermatitis-treatment/2460397/Hoth Therapeutics, Inc. has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic dermatitis. This agreement serves as an extension to the previo
- New Medscape Physician Compensation Report: Derms Earn About $411Khttps://practicaldermatology.com/news/new-2020-medscape-physician-compensation-report-derms-earn-about-411k/2460394/The 2020 Medscape Physician Compensation Report is out, and it shows that dermatologists earn an average of $411K per year, down 2 percent from 2019. Plastic surgeons earn $479K per year on average, up 2 percen
- Galderma: Patients Treated with Dysport Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Yearhttps://practicaldermatology.com/news/galderma-patients-treated-with-dysport-achieved-high-levels-of-satisfaction-and-natural-looking-results-with-two-treatments-per-year/2460391/Topline results of DREAM (Dysport Real-world Evaluation and Measured satisfaction study), a clinical study of Dysport (abobotulinumtoxinA) for injection, showed that 95 percent of patients treated with Dysport achieved high levels of satisfaction with two treat
- Done Deal: AbbVie Completes Acquisition of Allerganhttps://practicaldermatology.com/news/done-deal-abbvie-completes-acquisition-of-allergan/2460389/AbbVie completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court. In connection with the closing of the transaction, the AbbVie Board of Directors has elec
- Industry Responds to COVID-19: Allergan Foundation Doubles Down on COVID-19 Donationshttps://practicaldermatology.com/news/industry-responds-allergan-foundation-doubles-down-on-covid-19-donations/2460385/The Allergan Foundation fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic, doubling their COVID-19 donations to date, raising the total to $4 million. The donations are dedicated to 57 organ
- Survey: Social Media Isn’t All That Helpful for Growing Your Derm Practicehttps://practicaldermatology.com/news/survey-social-media-isnt-all-that-helpful-for-growing-your-derm-practice/2460384/Patients often do not take social media into consideration when looking for a dermatologist, according to a survey from researchers at the George Washington University. The survey appears in the Journal of Drugs in Derma
- Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of mPVhttps://practicaldermatology.com/news/cabaletta-bio-receives-fda-fast-track-designation-for-dsg3-caart-for-the-treatment-of-mpv/2460383/The U.S. Food and Drug Administration (FDA) granted Cabaletta Bio’s DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells) Fast Track Designation for improving healing of mucosal blisters in patients with mPV. DSG3-CAART is designed to specifically target the cause of mP
- 2020 RealSelf Sun Safety Report: Majority of Americans Don’t Use Sunscreen Dailyhttps://practicaldermatology.com/news/realself-sun-safety-report-majority-of-americans-dont-use-sunscreen-daily/2460381/The recently released 2020 RealSelf Sun Safety Report found that 62 percent of Americans use anti-aging products as part of their daily skincare routine, but only 11 percent wear sunscreen daily and 46 percent never wear
- Suneva to Distribute Sinclair Pharma's Silhouette Instalift Sutureshttps://practicaldermatology.com/news/suneva-to-distribute-sinclair-pharmas-silhouette-instalift-sutures/2460372/Suneva Medical, Inc. is the exclusive North American distributor for Sinclair Pharma's Silhouette Instalift sutures "We are excited to welcome Silhouette Instalift to our already broad regenerative aesthetics portfolio,"
- FDA Approves Ortho Dermatologics' Jublia to Treat Onychomycosis in Patients As Young As Six Years Oldhttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-jublia-to-treat-onychomycosis-in-patients-as-young-as-six-years-old/2460371/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics received FDA approval for a supplemental New Drug Application (sNDA) for Jublia (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range incl